Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02330497
Other study ID # RFAP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2015
Est. completion date February 2017

Study information

Verified date June 2018
Source Société Française d'Endoscopie Digestive
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Advances in conventional imaging (abdominal ultrasound, CT scan, MRI) are so great that chance to discover a incidental solid or cystic pancreatic lesion is becoming usual. Endocrine tumors have variable malignant potential depending on their size, some malignancy for lesions larger than 2 cm and indefinite for a smaller size. The branch-duct like IPMN (intraductal papillary mucinous pancreatic tumor) involving the pancreatic secondary ducts represent half of pancreatic cystic tumors and may degenerate into 5 to 10% of cases. Signs and risk of degeneration are the presence of mural nodules greater than 5 mm and size > 3 cm, although the latter criterion is discussed. Mucinous cystadenomas could degenerate between 30 and 50% of cases even though the role of size is much discussed (<4 cm). The follow-up imaging is performed using MRI and endoscopic ultrasonography (EUS). A fine needle aspiration for cytology and histology is possible and determination of biological markers is useful. But cytology is often unprofitable due to the poor cellular profile of the cystic pancreatic tumor. Once the diagnosis of suspected malignancy, the patient should be referred to the surgeon for pancreatic resection more or less extensive. But this attitude is facing a significant operative risk with up to 30% of morbidity and mortality between 1 and 3 % for cephalic resections. Some patients with high post operative risks are inoperable. For these reasons, some teams have proposed the destruction of the walls of the cyst under EUS, US or CT control by washing with absolute alcohol content of cystic tumor.

An interesting alternative endoscopic destruction would be the use of radio frequency ablation technique (RFA). RFA is a recognized technique for local tumor destruction by delivering thermal energy to obtain coagulation necrosis of the lesion. Taewong Medical ™ recently developed a radiofrequency needle EUSRA® coupled with a combo VIVA ™ generator for applying RFA sub EUS control. But no prospective study is available at this date regarding the treatment of the cystic or solid tumoral pancreatic lesion with this technique. The primary endpoint of the present study is to investigate the feasibility and safety of this guided radiofrequency probe EUS for the treatment of pancreatic endocrine tumors or inoperable pancreatic cystic tumors. The secondary objective will be the efficiency.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Pancreatic neuro endocrine tumor <2 cm confirmed by pathological reading, or mucinous cystic tumor (branch duct like IPMN with nodule wall > 5 mm unresectable) or mucinous cystadenoma with unresectable wall thickening

- Unresectable patient or high operative risk

- Multidisciplinary Collaborative Meeting confirming the indication for treatment.

- Patients who consented to participate in the study

- American Society Anesthesiology classification 1, 2 or 3

- Patient affiliated to the national social security system (beneficiary or assignee)

Exclusion Criteria:

- Invasive carcinoma lesions in a patient whose clinical condition allows to consider a surgical pancreatic resection

- Severe coagulopathy (PT <50%, partial thromboplastin time > 42 sec), thrombocytopenia (<75,000 G/L), antiplatelets agent

- Patient under anticoagulant agent (NACO, heparin and warfarin)

- American Society Anesthesiology classification 4

- Patient belonging to a so-called vulnerable patient population (pregnancy, nursing, patient trust, guardianship, private patient freedom, ...)

- Women of childbearing age, including in contraception

- Pace maker

- Inability to obtain informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Radiofrequency Ablation under EUS
Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session

Locations

Country Name City State
France Barthet Marseille

Sponsors (1)

Lead Sponsor Collaborator
Société Française d'Endoscopie Digestive

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of the pancreatic radiofrequency ablation under EUS guidance using the Cotton Classification At 3 months
Secondary Efficiency of the pancreatic radiofrequency ablation under EUS guidance Decrease of the size of the lesion using CT-scan and tumoral response using the Response Evaluation Criteria in Solid Tumors criterion At month 6 and 12
Secondary Safety of the pancreatic radiofrequency ablation under EUS guidance using the Cotton Classification At 7 days, one month, 6 and 12 months
See also
  Status Clinical Trial Phase
Completed NCT01673334 - Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Phase 4
Recruiting NCT01978808 - Efficiency Study of the EUS-FNA Needles With and Without a Side Port in Pancreatic Masses N/A
Completed NCT01479803 - Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUS Phase 3
Completed NCT02716207 - Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife N/A
Withdrawn NCT01434550 - Phase II Study of First-line SBRT in Patients With Non-Metastatic Unresectable Pancreatic Cancer N/A
Completed NCT03444051 - Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors N/A
Recruiting NCT05794048 - METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors N/A
Recruiting NCT05871164 - Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency
Recruiting NCT03558945 - Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor Phase 1
Recruiting NCT01969110 - Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Phase 4
Completed NCT01692873 - Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors N/A
Recruiting NCT04075305 - The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Recruiting NCT04357483 - Effect of Thrombin-containing Collagen-based Hemostatic Matrix Phase 4
Recruiting NCT01698190 - Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions N/A
Completed NCT03340844 - Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors N/A
Withdrawn NCT02534246 - Head to Head Comparison of Two Needles EUS Guided FNB N/A
Not yet recruiting NCT01819961 - Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Phase 4
Withdrawn NCT02269683 - Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer N/A